The primary goal of Кораксан (Ivabradine) therapy is to provide symptomatic relief and improve the management of specific chronic cardiac conditions where the patient has a persistently elevated heart rate. This medication is commonly used across therapeutic domains involving chronic stable angina and symptomatic chronic heart failure.

---

Easing Symptoms of Chronic Stable Angina

This medication is used for the symptomatic management of chronic stable angina pectoris, a condition where patients experience recurring symptoms related to physical discomfort such as chest heaviness, pressure, or squeezing. It is applied when the patient is in normal sinus rhythm and has a persistently elevated heart rate. The primary patient benefit is the support it provides in easing the overall symptom burden and managing symptoms that interfere with daily comfort, which helps patients cope more steadily with symptom fluctuations. This medication is commonly used across therapeutic domains involving chronic stable angina and symptomatic chronic heart failure.

---

Supportive Care for Chronic Heart Failure

Кораксан plays a supportive role in treating symptomatic chronic heart failure with reduced pumping function (HFrEF), particularly in adult patients with a heightened physiological activity who are in sinus rhythm. It is relevant for easing symptoms related to systemic imbalance such as excessive fatigue, shortness of breath, and reduced energy. The key patient benefit is its role in supporting stability, which may help maintain functional stability and ease the overall symptom load when symptoms are more noticeable. The medication is also applied in situations involving specific forms of stable heart failure in pediatric patients (6 months and older).

“The primary goal is to support stability and ease the overall symptom load in patients with a heightened physiological activity.”

Quick Fact: Relief for Cardiac Symptoms
Core Therapeutic Focus	Symptom management in chronic cardiac conditions
Primary Symptom Focus	Angina (chest discomfort), fatigue, shortness of breath
Key Benefit	Supports stability; contributes to easing the overall symptom load
Relevant Patient Groups	Adults with HFrEF or chronic angina; children with stable DCM

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Who Can and Cannot Use Кораксан (Ivabradine)?

The eligibility for Кораксан is strictly determined by official regulatory bodies, primarily based on the patient's existing heart rate, rhythm, and co-occurring conditions. The medicine is generally intended for adults and for pediatric patients aged 6 months and older for specific heart failure conditions.

Official Contraindications (Who Must Not Use)

Condition/Status	Restriction
Heart Rate	Resting heart rate below 70 beats per minute (bpm) (criteria may vary by region).
Cardiac Rhythm	Sick sinus syndrome, sino-atrial block, 3rd-degree Atrioventricular (AV) block, or pacemaker dependence.
Systemic State	Severe hypotension (e.g., blood pressure < 90/50 mmHg) or severe hepatic insufficiency.
Pregnancy/Lactation	Contraindicated in pregnancy; breastfeeding is not recommended.
Acute Conditions	Acute decompensated heart failure, cardiogenic shock, or unstable angina.

Restricted or Conditional Use

Use is not recommended in patients with conditions like Atrial Fibrillation or 2nd-degree AV block. Caution is advised in patients with severe renal impairment or moderate hepatic impairment.

Interactions with other medicines and products

The interaction profile for Coraxan (ivabradine) is primarily defined by its metabolism and its pharmacological effect on heart rate. Regulatory documents outline clear constraints based on these two mechanisms.

Interaction Type	Examples of Affected Substances	Regulatory Requirement
Metabolic (CYP3A4)	Strong inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin)	Contraindicated
Pharmacodynamic	Verapamil, Diltiazem, Other negative chronotropes (e.g., Beta-blockers)	Contraindicated (V/D) or Monitoring Required

Ivabradine is predominantly eliminated through the enzyme Cytochrome P450 3A4 (CYP3A4). Concomitant use with strong CYP3A4 inhibitors is strictly prohibited as it significantly increases ivabradine plasma concentrations, posing an unacceptable risk. The combination of ivabradine with non-dihydropyridine calcium channel blockers like verapamil and diltiazem is also contraindicated due to their dual roles as moderate CYP3A4 inhibitors and negative chronotropic agents.

It is officially not recommended to use ivabradine concurrently with CYP3A4 inducers, such as Rifampicin or the herbal product St. John's wort, as these substances decrease exposure and can lead to a loss of efficacy. Patients are advised to take the medication with meals, and the consumption of grapefruit juice is also not recommended due to its inhibitory effect on CYP3A4. Ivabradine is contraindicated in patients with severe hepatic impairment due to the expected increase in systemic exposure.

How Кораксан Works

Selective Inhibition of the Pacemaker Current

The drug operates by specifically and selectively blocking the If current (or "funny" current) in the heart’s sinoatrial node (the natural pacemaker). This mechanism involves interfering with the flow of ions through the HCN channels, which are responsible for spontaneously initiating each heartbeat. This precise molecular interaction is the primary step in the drug's overall mechanism of action.

Modulation of Cardiac Rhythmicity

By slowing the rate of electrical impulse generation, the drug prolongs the heart's diastolic phase (the resting/filling period), resulting in a pure, dose-dependent reduction in heart rate (a negative chronotropic effect). This action modulates the heart's rhythmicity without affecting the strength of the heart muscle's contractions (myocardial contractility).

Influencing Myocardial Oxygen Balance

The decreased heart rate is the key physiological consequence that influences the duration of the heart muscle's blood flow and its metabolic requirements, thereby adjusting the ratio of myocardial oxygen supply to demand. This action facilitates an adjustment in the cardiac system by decreasing the rate of work performed by the heart muscle.

Ivabradine (Кораксан) is administered exclusively through the oral route, with instructions mandating that the tablets or oral solution must be taken with meals twice daily, once in the morning and once in the evening. This consistent timing maintains the necessary drug concentration.

For most adults, the standard starting dose is 5 mg taken twice daily. The protocol emphasizes a titration schedule, where the dose is adjusted over 2 to 4 week intervals to guide the resting heart rate toward the specified range of 50 to 60 beats per minute (bpm). The maximum adult dose is 7.5 mg twice daily. If the resting heart rate falls persistently below 50 bpm, a dose reduction is required.

Specific population adjustments are outlined for administration. For example, patients 75 years of age and older should typically initiate treatment at a lower dose of 2.5 mg twice daily. The drug is available in 5 mg and 7.5 mg tablets; the 5 mg tablet is scored to facilitate the 2.5 mg dose. Dosing instructions for pediatric patients (6 months and older) are based on body weight, utilizing either the oral solution or tablets. In the event of a missed dose, guidance states that the subsequent dose should not be doubled to compensate.

Research Evidence and Overview of Studies for Кораксан

Evidence for Use in Symptom Management of Chronic Stable Angina

Ivabradine, or Кораксан, was studied for adult patients with chronic stable angina, a condition involving periods of heightened symptoms related to physical discomfort. Research primarily focused on patients who were in a normal heart rhythm (sinus rhythm) and had a persistently elevated resting heart rate. Large-scale Randomized Controlled Trials (RCTs) were used in research examining temporary physiological imbalance in this population.

Data show patterns related to heart rate measurements taken at rest and during activity. Studies report how symptoms evolved in the observed populations, and reported patterns in patient-reported symptom burden, such as the frequency of angina attacks. However, results apply only to the populations studied. Data show patterns related to cardiovascular events were mainly observed only when researchers specifically analyzed the subgroup of patients who had a high baseline resting heart rate (typically ge 70 beats per minute).

Evidence for Use in Supportive Care for Chronic Heart Failure (HFrEF)

For chronic heart failure with reduced pumping function ( HFrEF), research was evaluated in large, pivotal Randomized Controlled Trials (RCTs) and subsequent systematic reviews. The main groups studied were adults with symptomatic HFrEF who were already receiving standard medical therapy, were in normal sinus rhythm, and had a resting heart rate ge 70 beats per minute.

The primary focus of these large studies was monitoring composite outcomes, specifically monitoring composite outcomes that included cardiovascular death and hospitalization for worsening heart failure. Other outcomes monitored included changes in the patient’s recorded functional limitations (such as NYHA functional class) and quality of life scores. Findings describe patterns observed in studies monitoring the composite outcome of hospitalization for heart failure or cardiovascular death, and these observations were specific to the patient groups defined by the entry criteria.

What Is Still Uncertain About the Research for Кораксан

Evidence highlights what is known — and what is still uncertain — regarding Ivabradine. Comparative evidence is lacking for how Ivabradine performs against all alternative treatments in various subgroups. Research is ongoing, and certainty remains low regarding the full effect in patients with heart failure who have a heart rate below the studied threshold of HR < 70 beats per minute. The results apply only to the populations studied, and data are still emerging, meaning there is limited research regarding its use in patients whose heart function is preserved ( HFpEF).

Key Studies & References

1. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial
2. Ivabradine: MedlinePlus Drug Information

Common questions about Кораксан (FAQ)

Q: What is Кораксан (Coraxan) used for?

Кораксан (Ivabradine) is a prescription medication indicated for the symptomatic treatment of chronic stable angina pectoris in adults with normal sinus rhythm who have a contraindication or intolerance to beta-blockers. It is also indicated for the treatment of chronic heart failure (CHF) with a reduced ejection fraction in adult patients whose heart rate is 75 beats per minute (bpm), in combination with standard therapy.

Q: How does Кораксан work in the body?

Кораксан functions primarily by acting on the If ('funny' current) channel in the sinoatrial node of the heart. This action is specific to the heart rate and results in a selective reduction of the heart rate. By slowing the heart rate, the drug reduces the heart's oxygen demand, which helps relieve angina symptoms, and may contribute to clinical benefits in chronic heart failure. It does not affect blood pressure or myocardial contractility directly.

Q: How long does it take for Кораксан to start working for angina symptoms?

For most individuals, a reduction in heart rate, which is the mechanism that helps to relieve angina symptoms, is typically observed within 24 hours of starting treatment. However, the full beneficial effect on reducing the frequency of angina episodes is generally assessed after several weeks of consistent use. A healthcare provider will determine if the treatment is having the intended effect during follow-up assessments.

Q: What are the possible side effects associated with Кораксан?

As with all medications, Кораксан may cause side effects, though not everyone experiences them. The most common side effects are usually related to its mechanism of action and may include visual phenomena (such as temporary increased brightness in a limited area of vision, often described as luminous circles or halos), and slow heart rate (bradycardia). Less common side effects reported in clinical trials include headache and dizziness. A full discussion of potential risks and benefits should occur with a healthcare professional.

Q: Can Кораксан be taken with other heart medications, such as beta-blockers or calcium channel blockers?

Combining Кораксан with beta-blockers is not generally recommended, as the primary indication for using Ivabradine is for patients who cannot tolerate or have contraindications to beta-blockers. Combining it with certain non-dihydropyridine calcium channel blockers that slow the heart rate (such as diltiazem or verapamil) is contraindicated due to the risk of excessive heart rate reduction. Always inform your healthcare professional about all medications, supplements, and herbal products you are taking to ensure treatment safety and appropriateness.

Q: Is it safe to stop taking Кораксан suddenly?

Stopping Кораксан suddenly is generally not recommended without consulting a healthcare professional. Although abrupt cessation is not associated with a specific rebound effect, the underlying heart condition (angina or heart failure) for which the drug was prescribed may worsen or become less controlled. Any decision to adjust, stop, or change the dose of this medication must be made under the direct guidance of a prescribing clinician.

Official Storage and Handling Requirements

Coraxan (ivabradine) tablets and oral solution must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C. The medication must be kept in the original container, which should be tightly closed and stored away from excess heat and moisture.

For the oral solution, ampules must remain in the original foil pouch until use to protect the solution from light. The medication must be kept out of the sight and reach of children.

Disposal and Stability Rules

Any unused Coraxan oral solution remaining in the medication cup or the opened ampule must be discarded immediately and must not be saved or reused. Disposal of expired or unused medication must follow local and national regulatory requirements to prevent accidental exposure.